The study of bladder-preserving therapy with combined proton irradiation and intraarterial infution of anti-tumor agents in locally advanced bladder carcinoma.
| Project/Area Number |
02670698
|
|---|
| Research Category |
Grant-in-Aid for General Scientific Research (C)
|
| Allocation Type | Single-year Grants |
|---|
| Research Field |
Urology
|
|---|
| Research Institution | TSUKUBA University |
|---|
Principal Investigator |
OHTANI Mikinobu Clinical Medicine. Analogy. Assistant Professor, 臨床医学系, 講師 (80133081)
|
|---|
| Project Period (FY) |
1990 – 1992
|
| Project Status |
Completed (Fiscal Year 1992)
|
| Budget Amount *help |
¥1,600,000 (Direct Cost: ¥1,600,000)
Fiscal Year 1992: ¥500,000 (Direct Cost: ¥500,000)
Fiscal Year 1991: ¥600,000 (Direct Cost: ¥600,000)
Fiscal Year 1990: ¥500,000 (Direct Cost: ¥500,000)
|
|---|
| Keywords | Bladder Carcinoma / Intraarterial Infusion / Proton / Radiotherapy / Bladder Preservation / 膀胱保存 |
|---|
| Research Abstract |
Between August 1990 and December 1992, 21 patients with locally advanced (T2, 3 N0 M0) bladder carcinoma were treated with intraarterial infusion of anti-chemotheraputic agents and radiotherapy to preserve the bladder. Cisplatin (50mg/kg) and methotrexate (30 mg/kg) were administered via bilateral internal iliac artery infusion every 3 weeks (in total 3 times). Concurrently small pelvic field irradiation was performed with X -rays (41.4Gy), then if complete responce was achieved, proton beam irradiation (33Gy) to the original tumor site was followed.
A complete responce (CR) was seen in 19 patients (90.5%) and the other 2 patients were regarded as partial rsponders. Three of 19 complete responders underwent total cystectomy because they could not comfirm CR before cystecomy. Then, sixteen of the 19 complete responders and one of the 2 partial responders were preserved their bladders. Two of them were died of other diseases. Two patients in bladder-preserved group had recurrent tumors in their bladders. One was underwent total cystectomy and the other was controlled transurethral coagulation. The bladder function was preserved in thirteen patients and they have survived for a mean of 13.5 months (range 3-27) after the therapy without no evidence of disease. No severe side effects were observed in all patients.
From these preliminary results it is concluded that this therapy is viable regimen and could be considered as a means of preserving the bladder in patients with locally advanced bladder carcinoma.
|
Report
(4 results)
Research Products
(7 results)
